Acute migraine therapy: The newer drugs

Current Opinion in Neurology

Volumn 10, Issue 3, 1997, Pages 237-243

  Schoenen, Jean ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 METHOXYPHENYL) 2 [2 (2 METHOXYPHENYL)PROPIONYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 OL; ALNIDITAN; ANTIMIGRAINE AGENT; AVITRIPTAN; BOSENTAN; ELETRIPTAN; RIZATRIPTAN; RO 91274; SUMATRIPTAN; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BIOAVAILABILITY; CENTRAL NERVOUS SYSTEM; DROWSINESS; DRUG PENETRATION; DURA MATER; EXTRAVASATION; HUMAN; LIPOPHILICITY; MIGRAINE; NONHUMAN; PLASMA; RAT; RECURRENT DISEASE; REVIEW; THORAX DISEASE;

EID: 0030841055     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199706000-00012     Document Type: Review

References (38)

1. Tfelt-Hansen P: Drug treatment of migraine: acute treatment and migraine prophylaxis. Curr Opin Neurol 1996, 9:211-213.
2. Visser WH, de Vriend RHM, Jaspers NHWM, Ferrari MD: Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology 1996, 47:46-51. This 2-year Dutch experience of sumatriptan in clinical practice highlights its efficacy profile and shortcomings.
3. Dahlöf C: How does sumatriptan perform in clinical practice? Cephalalgia 1995, 15(suppl 15):21-28.
4. Visser WH, de Vriend RHM, Jaspers NHWM, Ferrari MD: Sumatriptan-nonresponders: a survey in 366 migraine patients. Headache 1996, 36:471-475 A clear risk factor for nonresponse to sumatriptan was not identified in this clinical analysis.
5. Visser WH, Burggraaf J, Muller LM, Schoemaker R, Fowler PA, Cohen AF, Ferrari MD: Pharmacokinetic differences between migraine patients with and without headache relief and between patients with and without headache recurrence after sumatriptan. Br J Clin Pharmacol 1995, 39:572-578. The authors show that nonresponse or headache recurrence after sumatriptan administration are not caused by pharmacokinetic differences.
6. Dβ receptor and clinical response to sumatriptan [Abstract]. Funct Neurol 1996, 11:149.
7. 1 receptor agonists in the acute treatment of migraine. Clinical, epidemiological and pharmacological aspects. Delft: Eburon-Delft; 1996.
8. Rapoport AM, Visser WH, Cutler NR, Alderton CJ, Paulsgrove LA, Davis RL, Ferrari MD: Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan. Neurology 1995, 45:1505-1509. This controlled trial demonstrated that headache recurrence after subcutaneous sumatriptan can not be prevented by 100 mg oral sumatriptan taken 4 h after the injection.
9. Mueller L, Gallagher RM, Ciervo CA: Vasospasm-induced myocardial infarction with sumatriptan. Headache 1996, 36:329-331. This case report reminds that cardiac safety remains an issue of concern with sumatriptan (and its follower triptans).
10. Sternfeld B, Stang P, Sidney S: Relationship of migraine headaches to experience of chest pain and subsequent risk for myocardial infarction. Neurology 1995, 45:2135-2142.
11. Göbel H, on behalf of the study group: A placebo-controlled, dose-defining study of sumatriptan suppositoires in the acute treatment of migraine. In Headache treatment: trial methodology and new drugs. Edited by Olesen J, Tfelt-Hansen P. Philadelphia: Lippincott-Raven Publishers; 1997:203-206.
12. Becker WJ, on behalf of the study group: A placebo-controlled, dose-defining study of sumatriptan nasal spray in the acute treatment of migraine. In Headache treatment: trial methodology and new drugs. Edited by Olesen J, Tfelt-Hansen P. Philadelphia: Lippincott-Raven Publishers; 1997:207-211.
13. Massiou H: A comparison of sumatriptan nasal spray and intranasal dihydroergotamine (DHE) in the acute treatment of migraine [Abstract]. Funct Neurol 1996, 11:151. This trial, which is yet to be published in detail, shows that intranasal sumatriptan is superior to DHE nasal spray in acute antimigraine treatment.
14. Winner P, Ricalde O, Le Force B, Saper J, Margul B: A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996, 53:180-184. The long awaited comparative trial of sumatriptan and DHE in subcutaneous formulations shows superior efficacy at 2 h of the former, but less headache recurrence after the latter.
15. Brennum J, Brinck T, Schiver L, Wanscher B, Soelberg Sorensen P, Tfelt-Hansen P, Olesen J: Sumatriptan has no clinically relevant effect in the treatment of episodic tension-type headache. Eur J Neurol 1996, 3:23-28.
16. Rederich G, Rapoport A, Cutler N, Hazelrigg R, Jamerson B: Oral sumatriptan for the long-term treatment of migraine: clinical findings. Neurology 1995, 45(suppl 7):S15-S20.
17. Rapoport AM, Cady RK, Mathew NT, Ramadan NM, Taylor FR, Saper FR, Earl NL, Brown DL, for the US 311C90 study group: Optimizing the oral dose of 311C90 in the acute treatment of migraine. Cephalalgia 1995, 115(suppl 12):221. This dose-finding trial of zolmitriptan suggested that the 2.5 mg dose has the optimal efficacy/adverse event ratio.
18. 1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology 1996, 46:522-526. This is the first placebo study at the 5, 10, 15 and 20 mg doses, but showed a higher incidence of CNS adverse effects for 15 and 20 mg.
19. Dahlöf C, Diener HC, Goadsby PJ, Massiou H, Olesen J, Schoenen J, Wilkinson M, Sweet RM, Klein KB: A multicentre, double-blind, placebo-controlled, dose-range finding study to investigate the efficacy and safety of oral doses of 311C90 in the acute treatment of migraine [Abstract]. Headache 1995, 35:292. This large multicentre trail confirmed superiority of zolmitriphan over placebo at the 5, 10, 15 and 20 mg doses, but showed a higher incidence of CNS adverse effects for 15 and 20 mg.
20. Färkkilä M, for the Eletriptan Steering Committee: A dose-finding study of eletriptan (UK-116,044) (5-30 mg) for the acute treatment of migraine [Abstract]. Cephalalgia 1996, 16:387.
21. Jackson NC, for the Eletriptan 7teering Committee: A comparison of oral eletriptan (UK-116,044) (20-80 mg) and oral sumatriptan (100 mg) in the acute treatment of migraine [Abstract]. Cephalalgia 1996, 16:368. The results of this clinical trial of eletriptan, published in abstract form, showed that high doses (40 and 80 mg) have superior efficacy over sumatriptan 100 mg.
22. Fletcher PE, Lowy MT, for the international 311C90 long-term study group: Evaluation of the long-term safety and efficacy of zolmitriptan (311C90) in the treatment of migraine. In Headache treatment: trial methodology and new drugs. Edited by Olesen J, Tfelt-Hansen P. Philadelphia: Lippincott-Raven Publishers: 1997:273-278. This long term study of zolmitriptan 5 mg demonstrated consistency of efficacy and excellent tolerance.
23. Diener HC, Klein KB, for the multinational oral 311C90 and sumatriptan comparative study group: The first comparison of the efficacy and safety of 311C90 and sumatriptan in the treatment of migraine [Abstract]. Funct Neurol 1996, 11:152.
24. Schoenen J, Klein KB, for the multinational oral 311C90 and sumatriptan comparative study group: 311C90 and sumatriptan produce indistinguishable CNS adverse event profiles [Abstract]. Cephalalgia 1996, 16:389.
25. Klein KB: A review of the efficacy of zolmitriptan (311C90): a new acute treatment for migraine. In Headache treatment: trial methodology and new drugs. Edited by Olesen J, Tfelt-Hansen P. Philadelphia: Lippincott-Raven Publishers; 1997:263-272.
26. Cutler NR, Claghorn J, Sramek JJ, Block G, Panebianco D, Cheng H, Olah TV, Reines SA: Pilot study of MK-462 in migraine. Cephalalgia 1996, 16:113-116. This is the first published trial of rizatriptan confirming the results of the larger study presented by Visser in her thesis [7] (i.e. remarkable efficacy of the 40 mg dose exceeding that of 100 mg sumatriptan but at the expense of a high rate of drowsiness).
27. Couch JR Jr, Saper J, Meloche JP, for the North American BMS 180048 Study Group: Treatment of migraine with BMS 180048: response at 2 hours. Headache 1996, 36:523-530. This trial demonstrated good antimigraine efficacy of avitriptan, development of which is suspended for toxicity concerns.
28. Goldstein J, Schellens R, Diener HC, Dahlöf C, Olesen J, Sénard JM, Steiner TJ, Simard D, on behalf of the Alniditan SC Dose-Finding Study Group: Alniditan, a novel nonindole 5-HT1D receptor agonist. In Headache treatment: trial methodology and new drugs. Edited by Olesen J, Tfelt-Hansen P. Philadelphia: Lippincott-Raven Publishers: 1997:279-285. The authors report excellent efficacy of subcutaneous alniditan at doses ranging from 0.8 to 1.4 mg and lower headache recurrence rates for the 1.4 mg dose.
29. Connor HE, Feniuk W, Beattie DT, Saynor DA, Humphrey PPA: Naratriptan: profile of action in animal models relevant to migraine [Abstract]. Eur J Neurol 1996, 3(suppl 5):86.
30. Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-fos and electrophysiologlcal study. Brain 1996, 119:249-256.
31. 1B/D receptors in the brain stem.
32. Schoenen J, Proietti Cecchini A, Áfra J: Evidence for a central effect of a 5-HT1D agonist, 311C90, from a study of the intensity dependence of cortical auditory evoked potential. Eur J Neurol 1996, 3(suppl 5):88. This is the first demonstration of a central effect of zolmitriptan in humans.
33. Mitsikostas DD, Papadopoulou-Daifoits Z, Sfikakis A, Varonos D: The effect of sumatriptan on brain monoamines in rats. Headache 1996, 36:29-31.
34. Thomaides T, Tagaris G, Karageorgiou C: EEG and topographic frequency analysis in migraine attack before and after sumatriptan infusion. Headache 1996, 36:111-114.
35. 1D (alpha) autoreceptors in midbrain raphe nuclei.
36. May A, Gijsman HJ, Wallöfer A, Jones R, Diener HC, Ferrari MD: Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 1996, 67:375-378. This is the first trial showing that a compound, bosentan, that is highly effective in inhibiting neurogenic plasma extravasation in rat dura mater has no efficacy in aborting migraine attacks.
37. Maizels M, Scott B, Cohen W, Chen W: Intranasal lidocain for treatment of migraine. A randomized, double-blind, controlled trial. JAMA 1996, 276:319-321. Controlled trial showing that at 5 min the responder rate after intranasal lidocaine 4% exceeds that of placebo by 24%.
38. Mauskop A, Altura BT, Cracco RQ, Altura BM: Intravenous magnesium sulfate rapidly alleviates headaches of various types. Headache 1996, 36:154-160.